At the 2019 meeting, almost 500 presentations discussed new randomized controlled trials. We are lucky to have so much research activity in our field, but applying an RCT to your daily practice can be challenging. Here are three tips to supercharge your critical appraisal!

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.

A disease you’ve never heard of is becoming increasingly common and carries a very poor prognosis.  For me, one of most important aspects of attending the ACR Annual Meeting is to learn about conditions that I don’t know and that may afflict my patients when I return back home. This year’s meeting was no different.